- Motif Bio has received written concurrence from the US Food & Drug Administration (FDA) for an optimized fixed dose of iclaprim of 80mg for all patients except those with moderate hepatic impairment, regardless of bodyweight, in the Company's proposed Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections.

The fixed dose of iclaprim, together with the selected infusion time, optimizes pharmacodynamic parameters associated with antibacterial efficacy, while potentially minimizing safety events.

At 9:30am: [LON:MTFB] Motif Bio Plc Ord 1p share price was -0.75p at 55.25p

Story provided by